Adverse drug reactions (ADRs) are a major public health problem. Pharmacogenetic testing prior to drug treatment is supposed to considerably alleviate this problem. The state of pharmacogenetic development was assessed by a systematic literature review, supplemented by expert interviews. Analysis of three case examples revealed that – with the exception of thiopurine methyltransferase (TPMT) – studies are lacking which unambiguously prove the clinical value of pharmacogenetic testing. Testing can prevent some, but by far not all ADRs. Since it does not compensate for clinical monitoring, pharmacogenetics can be regarded as add-on technology, applied in addition to established methods. A non-representative, explorative survey conducted amongst members of the German Society of Laboratory Medicine revealed that the demand for testing is limited and has not increased much, although a certain increase is expected in the future.

Keywords:
Adverse drug reactions, Pharmacogenetics, Public health, Testing
1.
Abbott A: With your genes? Take one of these, three times a day. Nature 2003;425:760–762.
2.
Schneeweiss S, Hasford J, Göttler M, et al: Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:285–291.
3.
Schönhöfer PS, Lelgemann M, von Maxen A, Wille H: Häufigkeit von Arzneimittelrisiken und Risikokommunikation; in Hart D, Kemmnitz W, Schnieders C (eds): Arzneimittelrisiken: Kommunikation und Rechtsverfassung. Baden-Baden, Nomos, 1998, pp 109–120.
4.
Schnurrer JU, Frölich JC: Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkungen. Internist 2003;44:889–895.
5.
Mancinelli L, Cronin M, Sadee W: Pharmacogenomics: the promise of personalised medicine. AAPS Pharmsci 2000;2:4.
6.
Weinshilboum R: Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601–605.
7.
Kollek R, Feuerstein G, Schmedders M, van Aken J: Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen. Baden-Baden, Nomos, 2004.
8.
van Aken J, Schmedders M, Feuerstein G, Kollek R: Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003;3:149–155.
9.
Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025–1030.
10.
Schwabe U, Paffrath D: Arzneiverordnungsreport 2002. Berlin, Springer, 2003.
11.
Wuttke H, Rau T, Heide R, et al: Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429–437.
12.
Pirmohamed M, Park BK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192:23–32.
13.
Wuttke H, Rau T, Eschenhagen T: Genpolymorphismen in Arzneimittel-abbauenden Enzymen. Bedeutung für die Therapie mit β-Blockern. Dtsch Med Wochenschr 2004;129:831–835.
14.
Schwabe U, Paffrath D: Arzneiverordnungsreport 1999. Berlin, Springer, 2000.
15.
Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438–452.
16.
Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, et al: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105–119.
17.
Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmöller J: How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000;38:869–876.
18.
Lesko LJ, Woodcock J: Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002;2:20–24.
19.
Holtzmann NA: Clinical utility of pharmacogenetics and pharmacogenomics; in Rothstein MA (ed): Pharmacogenomics. Social, Ethical, and Clinical Dimensions. Hoboken, Wiley-Liss, 2003, pp 163–185.
20.
Melzer D, Detmer D, Zimmern R: Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 2003;4:689–691.
21.
Schmedders M, van Aken J, Feuerstein G, Kollek R: Individualized pharmacogenetic therapy: a critical analysis. Community Genet 2003;6:114–119.
22.
Feuerstein G, Kollek R, Schmedders M, van Aken J: Irreführende Leitbilder. Zum Mythos der Individualisierung durch pharmakogenetische Behandlungskonzepte. Ethik Med 2003;15:77–86.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.